The stock of Silence Therapeutics plc (LON:SLN) is a huge mover today! The stock closed at GBX 110 during the last session. It is down 12.00% since April 29, 2016 and is downtrending. It has underperformed by 17.26% the S&P500.
The move comes after 5 months negative chart setup for the GBX 77.51M company. It was reported on Nov, 29 by Barchart.com. We have GBX 103.40 PT which if reached, will make LON:SLN worth GBX 4.65 million less.
More news for Silence Therapeutics plc (LON:SLN) were recently published by: Prnewswire.com, which released: “Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi …” on December 16, 2009. Bloomberg.com‘s article titled: “AstraZeneca CEO Chases Multiple Strands in RNA Drug Quest” and published on March 28, 2013 is yet another important article.
Silence Therapeutics plc is a United Kingdom ribonucleic acid technology company. The company has a market cap of 77.51 million GBP. The Firm is primarily involved in the research and development of pharmaceutical products. It currently has negative earnings. The Company’s technology harnesses the body’s natural mechanisms to create therapeutic effects within its own cells.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.